《新生源商务模式精要中英文版》由会员分享，可在线阅读，更多相关《新生源商务模式精要中英文版（7页珍藏版）》请在金锄头文库上搜索。
1、新生源：实现生物医药的价值Newsummit Biophama: Actualizing the value of biomedicine加速新药成果产业化Accelerate the industrialization of new drug achievement加速生物产业资本化Speed the capitalization of the bio-industry加速科技资本国际化Quicken the internationalization of science and technology capital创新的活力 创业的激情 创优的机制（New Summit）上海新生源集团(N
2、ewsummit,NSB)于 2001 年，由以任军为首的创业团队以所获国家科技进步二等奖和上海首次实施科技成果转化政策的个人奖励 30 万元人民币注册创立。2008 年，新生源创新创业团队以中国公民身份，获得上海市外汇管理局批准 75 号文件，完成红杉资本和 Sansar 等国际投资基金 4400 万美金的投资。目前经营管理团队仍为第一大股东，其他投资方包括：上海科投、复旦创投和光明集团等。Innovative dynamism, entrepreneurial passion, mechanism for creating excellenceShanghai Newsummit Biop
3、harma Group (Newsummit, NSB) was found in 2001, led by Ren Juns group, have achieved second prize of the national scientific and technological progress and in shanghai the implementing of scientific and technological achievements for the first time awarded 300,000 Yuan. In 2008, the innovative ventu
4、re team, acted as Chinese citizenship, was approved by the Shanghai Foreign Exchange Administrative bureau No.75 document, completeing international investment funds like Sansar and Sequoia Capital which amounts 44 million U.S. dollars. Currently the management team will remain the largest sharehold
5、er, other investors include: Shanghai science and technology group, Fudan group and Guangming bloc etc.产业集群战略：新药研发产业链式公共服务孵化平台（PCRD）抓住“天时地利人和” ，新生源实施以 “官产学研资 ” 联盟为核心的 “蓝海战略”，依托国家生物医药产业基地和高新技术园区，建设政府引导、企业主导，促进成果转化和产业化实施的新药研发产业链式公共服务孵化平台（PCRD, Platform Chain of Research & Development） 。目前新生源在上海张江药谷承担新
6、药研发产业化加速器，投资 1.25 亿元人民币建设新药中试产业化研究平台和国际新药落地孵化基地（5000 M2） ；在江苏泰州中国医药城承担新药研发公共服务平台，投资 7500 万元人民币，建设科技大楼（24000M 2）和符合 cGMP 标准的新药 CRO-CMO 产业化基地（ 4000 M2） ；在武汉光谷生物城承担新药研发孵化服务平台，投资 5000 万元人民币，建设新药研究中试孵化基地（25000 M 2） ；在大连双 D 港和沈阳棋盘山承担新药研发公共服务平台，投资 5000 万元人民币（10000 M2） 。新生源初步形成高效集成、资源共享、集约配置、区域联动的网络化运营机制，实现
7、中国生物医药产业资源优化整合（CRO，China Resource Organization） 。Industrial Cluster Strategy: public service incubation platform chain of new drug R&D industryNSB seized the opportune and applied the “Blue Ocean Strategy” as the core to unite government, enterprise, universities and institution. Relying on state bi
8、omedical industry base and high and new tech area, under deep cooperation framework with government, NSB formed new drug public service platform chain of R&D to promote the transformation of achievement and implementing of industrialization. In shanghai pharma valley, NSB accelerated the industriali
9、zation of new drug research and invested 125 million Yuan to the construction of new drug research platform for industrialization and international new drug landing incubation bases（5000 M2） ；In Taizhou of Jiangsu province，city of Chinese medicine，acted as public service platform for new drug resear
10、ch and development, invested 75 million Yuan to construct science and technology building （24000M 2）and CRO-CMO industrialization base （4000 M2）which conform standard of cGMP. In Wuhan, biolake acted as service platform for new drug R&D and incubation, invested 50,000,000 Yuan to the construction of
11、 new research test incubation bases (25,000 M2) while Digital & DNA of Dalian and checkboard of Shenyang functioned as public service platform for new drug R&D, its investment up to 50 million Yuan. NSB initially formed the network operation mechanism of effective integration, resource sharing and i
12、ntensive configuration and regional cooperation, to realize resources organization of China biomedical industry (CRO).技术服务平台：新药研发的一站式技术服务体系（GRDP）在此基础上，新生源与复旦大学、交通大学、中科院生命科学院、军事医学科学院、中国医学科学院、英国皇家医学理事会（MRCT） 、法国癌症研究院（Cancer Campus） 、美国北卡州立大学、华盛顿大学、南加州大学、昆泰、Lilly、Astrazeneca 等国内外著名科研机构、技术服务机构和医药企业合作。基本
13、形成涵盖新药 IND/NDA 研发链的技术保障设施。以模块化、标准化、产业化的流水线方式提供新药研发的一站式技术服务体系 GRDP(Good Research and Development Practices)，技术服务包括：1）哺乳动物高效蛋白表达 2）新药质量研究 3）中试- 产业化研究和实验样品制备（cGMP）4）药理、毒理、药代等非临床研究组织（GLP）5）临床研究组织（GSP ） ，6）SFDA 和 FDA/EMEA申报 IND/NDA 组织，7）基于 GMP 标准的产业化研究和 GMP 认证。新生源承担“国家重大新药创制” （十一五第一批）骨干企业创新药孵化基地建设专项，全国唯一
14、的“产业化技术体系建设专项课题” 。Technical service platform: new drug R&D one-stop technique service system (GRDP)On this basis, NSB cooperated with famous research institutions, technical service institution and pharmaceutical enterprise, such as Fudan university，university of communication, Chinese academy of li
15、fe and sciences，military academy of medical sciences, the Chinese academy of medical sciences, British royal medical council (MRCT), Cancer institute, NCSU, the university of southern California, the university of Washington, Astrazeneca and so on. It basically form technical support facilities for
16、new drugs development of chain IND/NDA. With modularization, standardization, industrialization of pipeline system will provide new drug R&D one-stop technical service system, technical service including:1) mammals high protein expression 2) drug quality research 3) pilot - industrialization research and experiment of sample preparation(cGMP)(4) non-clinical research organization like pharmacology, toxicology (GLP) 5) clinical research organization (GSP), 6)declaration of
